Comparison of in-hospital and long-term outcomes between a Cypher stent and a Taxus stent in Chinese diabetic patients with coronary artery disease

被引:7
|
作者
Yang Yue-jin [1 ]
Xu Bo [1 ]
Kang Sheng [1 ]
Pei Wei-dong [1 ]
Chen Ji-lin [1 ]
Qiao Shu-bin [1 ]
Qin Xue-wen [1 ]
Yao Min [1 ]
Chen Jue [1 ]
Wu Yong-jian [1 ]
Liu Hai-bo [1 ]
You Shi-jie [1 ]
Li Jian-jun [1 ]
Dai Jun [1 ]
Gao Run-lin [1 ]
机构
[1] Chinese Acad Med Sci, Peking Union Med Coll, Fuwai Hosp, Cardiovasc Inst,Coronary Heart Dis Ctr,Dept Cardi, Beijing 100037, Peoples R China
关键词
diabetes; percutaneous coronary intervention; stent; outcomes;
D O I
10.1097/00029330-200711010-00003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The sirolimus and paclitaxel distribution patterns and tissue residence time may be modified in atherosclerotic lesions for patients with diabetes, and the biological mechanisms of action for these agents differ significantly. Previous clinical trials have yielded discrepant results of major adverse cardiac events and restenosis between a sirolimus-eluting stent and a paclitaxel-eluting stent in coronary artery disease. Therefore, this study was conduced to compare in-hospital and long-term clinical outcomes between patients receiving sirolimus-eluting stent (Cypher or Cypher Select stent) and paclitaxel-eluting stent (Taxus Express stent) after percutaneous intervention (PCI) in Chinese patients with diabetes. Methods One hundred and sixty-four consecutive diabetic patients underwent PCI in Fuwai Hospital from April 2004 to December 2004. Of them, 101 patients received Cypher or Cypher Select stents (Cypher group, 145 stents) and 63 patients received Taxus Express stents (Taxus group, 129 stents). Repeat coronary angiography was performed at 6-month and clinical outcomes were evaluated at 1- and 3-year follow-up. Stent thrombosis was classified according to Academic Research Consortium (ARC). Results The two groups did not differ significantly with respect to cardiac death, recurrent myocardial infarction (re-MI), target vessel revascularization (TVR) and occurrence of major adverse cardiac events (MACE). And the MACE-free cumulative survival at 1- and 3-year follow-up and early, late and very late thrombosis rates were also similar in the two groups (all P > 0.05). There was a trend favoring PES over SES with regard to reducing cardiac death (0 vs 2.0%, P=0.524), re-MI (0 vs 2.0%, P=0.524), the composite of the cardiac death and re-MI (0 vs 4.0%, P=0.299) and very late thrombosis (0 vs 3.0%, P=0.295) between 1-year and 3-year follow-up. Conclusion The study indicates that PCI with either Cypher or Taxus stents is associated with similar efficacy and safety in the small population of Chinese diabetic patients during long-term follow-up.
引用
收藏
页码:1868 / 1873
页数:6
相关论文
共 50 条
  • [21] Long-term outcomes of coronary-artery bypass grafting versus stent implantation
    Hannan, EL
    Racz, MJ
    Walford, G
    Jones, RH
    Ryan, TJ
    Bennett, E
    Culliford, AT
    Isom, OW
    Gold, JP
    Rose, EA
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (21): : 2174 - 2183
  • [22] Long-term prognostic impact of in-hospital cerebrovascular accidents and stent thrombosis in patients undergoing percutaneous coronary intervention
    Guerra, E.
    Ndrepepa, G.
    Schulz, S.
    Byrne, R.
    Cassese, S.
    Haase, U.
    Hadamitzky, M.
    Schunkert, H.
    Laugwitz, K. L.
    Kastrati, A.
    EUROPEAN HEART JOURNAL, 2014, 35 : 969 - 969
  • [23] Long-term outcomes after drug-eluting stent implantation in long calcified coronary artery disease.
    Nam, C. W.
    Hur, S. H.
    Kim, K. B.
    Cho, Y. K.
    Kim, H. S.
    Han, S. W.
    Kim, Y. N.
    AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (08): : 53F - 53F
  • [24] Comparison of efficacy and safety between sirolimus-eluting stent (Cypher) and paclitaxel-eluting stent (TAXUS) on the outcome of patients with diffuse in-stent restenosis
    Nakamura, S.
    Muthusamy, T. S.
    Bae, J. H.
    Cahyadi, Y. H.
    Udayachalerm, W.
    Tresukosol, D.
    Tansuphaswadikul, S.
    EUROPEAN HEART JOURNAL, 2005, 26 : 468 - 468
  • [25] Immediate and long-term outcomes of drug-eluting stent implantation for unprotected left main coronary artery disease: Comparison with bare-metal stent implantation
    Gao, Run-lin
    Xu, Bo
    Chen, Ji-lin
    Yang, Yue-jin
    Qiao, Shu-bin
    Li, Jian-jun
    Qin, Xue-wen
    Yao, Min
    Liu, Hai-bo
    Wu, Yong-jian
    Yuan, Jin-qing
    Chen, Jue
    AMERICAN HEART JOURNAL, 2008, 155 (03) : 553 - 561
  • [26] Comparison of efficacy and safety between Sirolimus-eluting stent (Cypher) and Paclitaxel-eluting stent (TAXUS) on the outcome of patients with diffuse in-stent restenosis
    Nakamura, S.
    Bae, J. H.
    Cahyadi, Y. H.
    Udayachalerm, W.
    Tresukosol, D.
    Tansuphaswadikul, S.
    EUROPEAN HEART JOURNAL, 2006, 27 : 654 - 654
  • [27] Comparison of efficacy and safety between sirolimus-eluting stent (Cypher™) and paclitaxel-eluting stent (TAXUS™) on the outcome of patients with diffuse in-stent restenosis
    Nakamura, S
    Bae, JH
    Cahyadi, YH
    Udayachalerm, W
    Tresukosol, D
    Tansuphaswadikul, S
    AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (7A): : 96H - 96H
  • [28] Long-term outcomes of 316 patients with STEMI following coronary stent implantation
    Li, Xiao-Wei
    Liu, Yin
    Gao, Ming-Dong
    Xiao, Jian-Yong
    Gao, Jing
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2022, 14 (06): : 4139 - 4145
  • [29] Immediate and long-term outcomes of coronary stenting in relation to stent implantation pressure in patients with coronary heart disease
    Puretskij, M.V.
    Abugov, S.A.
    Saakyan, Yu.M.
    Vestnik Rentgenologii i Radiologii, 2002, (05) : 13 - 19
  • [30] Impact of stent type and prolonged dual antiplatelet therapy on long-term clinical outcomes in hemodialysis patients with coronary artery disease
    Asami M.
    Aoki J.
    Sato T.
    Tanimoto S.
    Watanabe M.
    Horiuchi Y.
    Furui K.
    Yasuhara K.
    Sato Y.
    Hashimoto T.
    Yachi S.
    Hara K.
    Tanabe K.
    Cardiovascular Intervention and Therapeutics, 2018, 33 (1) : 84 - 94